JPRN-UMIN000011570招募中未知
The assessment of the response to everolimus of renal cell carcinoma by FDG PET/CT and its impact on prognosis - FDG-PET/CT assessment of response to everolimus in renal cell carcinoma
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who meet any of the following are excluded from the study. (1)Concurrent antitumor treatment other than everolimus is given. (2)Prior treatment with more or 2 tyrosine kinase inhibitors (3)Prior treatment of treatment with mTOR inhibitors (temsirolimus or everolimus) (4)Prior treatment with chemotherapy with antitumor drug, regardless of cytokine therapy (5)Poorly-controlled diabetes mellitus (fasting blood glucose more than 150 g/dL) (6)Pregnant and/or nursing woman, possibility of pregnancy (7)History of organ transplantation (including bone marrow transplantation) (8)History of malignancy except: (i)Curatively treated intraepithelial cervical cancer, basal cell carcinoma, superficial bladder cancer (Ta, Tis and T1). (ii)Patients who had been disease free more for than 3 years after curative therapy
研究者
相似试验
进行中（未招募）
1 期
Introduction of everolimus is associated with a reduction in the dosage of calcineurine-inhibitors in patients with a pulmonary graft who suffer from a notable chronic renal insuffisance.Patient who received a pulmonary transplant and who show notable renale insuffisance (DFG < 50ml/min/1.73m²) which has been progressive over the last two years or chronical renal insuffisance which progresses fast (a los of >50% DGF in 3 months) and isotopical glomerural filtration < 45 ml/min.EUCTR2006-001945-32-BEB Erasme15
招募中
Unknown
Clinical effects of everolimus in the subjects with autism spectrum disprders (ASD) in relation to tuberous sclerosis.there are a few individuals with TSC with SEGA who exhibite ASD symptoms.JPRN-jRCT1090220258Kunio Yui20
已完成
不适用
Assessment of efficy and safety of everolimus in Japanese patients with mRCCrenal cell carcinomaJPRN-UMIN000009620Tokyo Afinitor Clinical Trial Group200
招募中
2 期
Efficacy of 0.05%topical everolimus in the treatment of adenoma sebaceum in tuberous sclerosisadenoma sebaceumTCTR20180820002Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital15
进行中（未招募）
不适用
Everolimus and Fulvestrant therapy in postmenopausal metastatic Breast Cancer at patient treated with fulvestrant and who progressed on or after mTor inhibitor based treatmentpostmenopausal women with hormone receptor-positive, Her2 negative AI and fulvestrant treated, locally advanced or metastatic breast cancer, who progressed on prior fulvestrant and also received prior treatment with everolimus and exemestane. The treatment with fulvestrant is not required to be the last treatment administered as long as at some point in time a progression on fulvestrant has been ascertained.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-000665-36-BEZ Brussel